OncoMatch/Clinical Trials/NCT06242834
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Is NCT06242834 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Tazemetostat for b-cell non-hodgkin lymphoma.
Treatment: Pembrolizumab · Tazemetostat — This phase II trial tests how well pembrolizumab and tazemetostat work to treat patients who have received autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T cell therapy for aggressive non hodgkins lymphoma. A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tazemetostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and tazemetostat may work better to treat patients who have received ASCT or CAR-T cell therapy for aggressive non hodgkins lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: autologous stem cell transplant — intended for or currently undergoing
intended for or currently undergoing standard of care ASCT
Must have received: CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) — intended for or currently undergoing
intended for or currently undergoing standard of care CAR T-cell therapy
Cannot have received: anti-PD-1 therapy
prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent
Cannot have received: EZH2 inhibitor
prior exposure to EZH2 inhibitors
Cannot have received: radiotherapy
Exception: 1-week washout permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease
prior radiotherapy within 14 days of start of study intervention
Lab requirements
Blood counts
ANC ≥ 500/μL (growth factor allowed up to day prior to LDC/conditioning chemo); Platelets ≥ 50,000/μL (≥ 25,000 with bone marrow involvement); INR/aPTT ≤ 1.5 × ULN unless on anticoagulant and within therapeutic range
Kidney function
Creatinine clearance ≥ 30 mL/min estimated by Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x ULN (except Gilbert Syndrome < 3.0 mg/dL), OR direct bilirubin ≤ ULN if total bilirubin > 1.5 x ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN
Cardiac function
NYHA class 2 or better if cardiac history or risk
ANC ≥ 500/μL; Platelets ≥ 50,000/μL (≥ 25,000 with bone marrow involvement); Total bilirubin ≤ 1.5 x ULN (except Gilbert Syndrome < 3.0 mg/dL), OR direct bilirubin ≤ ULN if total bilirubin > 1.5 x ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN; Creatinine clearance ≥ 30 mL/min; INR/aPTT ≤ 1.5 × ULN unless on anticoagulant and within therapeutic range; NYHA class 2 or better if cardiac history or risk
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwestern University · Chicago, Illinois
- University of Iowa · Iowa City, Iowa
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify